Although biomarker testing is central to precision oncology, significant gaps remain in education, protocols, timeliness, and equity according to an article published this past June in the Journal of Managed Care & Specialty Pharmacy . According to the study’s authors, by adopting consensus-driven best practices, managed care organizations can play a pivotal role in ensuring that biomarker testing fulfills its promise, delivering more effective, equitable, and cost-conscious cancer care.

Precision medicine has changed oncology by making it possible to make therapy decisions based on molecular indicators that can be acted on. Timely biomarker testing can greatly enhance survival and treatment outcomes for malignancies like non-small cell lung cancer. Even if this is a good sign, adopti

See Full Page